Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 + Irinotecan Liposome (II) in ESCC After Immunotherapy
NCT07524374Phase 2Not yet recruiting
- Start
- Mar 2026
- Primary completion
- Sep 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retlirafusp alfa in Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoint: Objective Response Rate at 12 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07524374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07524374.